Vera Therapeutics, Inc. (VERA) Misses Q3 EPS by 21c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. DOX
3. BKNG
4. DUOL
5. SWKS
6. AMGN
7. ANET
8. XYZ
9. CVS
10. FISV

Go back to Vera Therapeutics, Inc. (VERA) Misses Q3 EPS by 21c

Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

November 9, 2022 7:30 AM EST

Phase 2b ORIGIN clinical trial of atacicept in IgA nephropathy topline data planned to be presented in early Q1 2023Initiated pivotal Phase 3 COMPASS clinical trial of atacicept in lupus nephritis Strong balance sheet with $114.4 million in cash, cash equivalents, and marketable securities as of September 30, 2022; together with credit facility, are expected to fund operations to Q2 2024

BRISBANE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its... More